CJC-1295, ipamorelin, and IGF-1 LR3 all affect the growth hormone–IGF-1 axis, but they are not the same. CJC-1295 and ipamorelin stimulate growth hormone release through different receptors, while IGF-1 LR3 is a modified IGF-1 analog. Human evidence is limited, and performance or longevity claims remain unproven.
Wondering if sermorelin is right for you? Take the 3-min clinical quiz.
See if you qualify →What are CJC-1295, ipamorelin, and IGF-1 LR3?
CJC-1295, ipamorelin, and IGF-1 LR3 are often discussed together because they sit near the same hormone system: growth hormone, insulin-like growth factor 1, and the tissues that respond to them. But their mechanisms are different, and that difference matters for expected effects, side effects, and the strength of the evidence.
CJC-1295: a growth hormone-releasing hormone analog
CJC-1295 is a long-acting growth hormone-releasing hormone, or GHRH, analog. In a randomized human study, CJC-1295 produced dose-dependent increases in growth hormone and IGF-1 in healthy adults, which supports its hormone-stimulating mechanism rather than any proven body-composition outcome 1.
You may see CJC-1295 discussed as CJC-1295 with DAC, meaning drug affinity complex, or as CJC-1295 without DAC, often called Modified GRF 1-29. These are related GHRH-type peptides, but they are not interchangeable names for a proven anti-aging treatment.
Ipamorelin: a growth hormone secretagogue and ghrelin receptor agonist
Ipamorelin, also called NNC 26-0161 in research, is a growth hormone secretagogue. That means it stimulates GH release, mainly through the ghrelin receptor, also called GHS-R1a. Human volunteer studies modeled its pharmacokinetics and GH response, but those studies did not prove muscle or fat-loss benefits 2.
IGF-1 LR3: a modified insulin-like growth factor analog
IGF-1 LR3, also called Long R3 IGF-1, is different because it is not mainly trying to make the pituitary gland release more GH. It is a modified IGF-1 analog that is discussed for more direct IGF-1 receptor signaling. The normal IGF-1 system is tightly regulated by IGF-binding proteins, which is one reason modified analogs raise safety questions when used outside approved clinical settings 7.
Why these peptides are often discussed together
They are discussed together because all three relate to the GH–IGF-1 axis. That does not mean they have the same evidence or the same risk profile. Reviews of performance-enhancing peptide use note that many online protocols move faster than the human evidence, especially for physique, recovery, and longevity claims 8.
| Peptide | Main pathway | Human evidence | Key caution |
|---|---|---|---|
| CJC-1295 | GHRH analog that stimulates pituitary GH release | Small human studies showing GH and IGF-1 biomarker changes | Biomarker changes do not prove muscle, fat-loss, or longevity outcomes |
| Ipamorelin | Ghrelin receptor agonist and GH secretagogue | Human pharmacology data and a postoperative ileus trial | Not proven for bodybuilding, anti-aging, or fat loss |
| IGF-1 LR3 | Modified IGF-1 analog acting closer to IGF-1 signaling | Limited direct human outcome evidence | Blood sugar, endocrine, and long-term mitogenic uncertainty |
| Sermorelin | GHRH analog that stimulates GH release upstream | Studied as a GHRH analog; compounded use requires clinician review | Chia offers sermorelin, but compounded medications are not FDA-approved |
How do these peptides work in the GH–IGF-1 axis?
The GH–IGF-1 axis is a feedback system. The brain and pituitary help control growth hormone pulses; GH then signals the liver and other tissues to produce IGF-1, which acts on many tissues and feeds back into the system.
The role of growth hormone, IGF-1, and IGF-binding proteins
Growth hormone is released in pulses, not as a flat line. IGF-1 then circulates in the blood, much of it bound to IGF-binding proteins, which help control how much free IGF-1 can signal at tissues 7.
How CJC-1295 may raise GH and IGF-1
CJC-1295 acts upstream by stimulating the GHRH receptor. In a clinical trial, pulsatile GH secretion persisted during continuous CJC-1295 stimulation, which supports the idea that it stimulates the body’s GH system rather than replacing GH directly 4.
How ipamorelin stimulates GH release
Ipamorelin works through the growth hormone secretagogue pathway, linked to the ghrelin receptor. In human volunteers, researchers modeled the relationship between ipamorelin exposure and GH response, but the study was pharmacology-focused rather than an outcomes trial 2.
How IGF-1 LR3 differs from stimulating your own GH
IGF-1 LR3 is closer to the downstream signal. Instead of asking the pituitary to release more GH, it is discussed as a modified IGF-1 analog. That may sound more direct, but direct signaling can also mean less normal feedback control and more concern about glucose changes, tissue growth signals, and long-term uncertainty 8.
Is IGF-1 LR3 better than CJC-1295 and ipamorelin?
IGF-1 LR3 is not proven to be better than CJC-1295 or ipamorelin for strength, muscle gain, fat loss, recovery, or longevity. “Better” depends on the clinical question, and for many popular use cases there are no strong human outcome trials.
Why “better” depends on the clinical question
A peptide that changes a lab marker is not automatically better for a person’s goal. A useful clinical question is specific: Is the goal a diagnosed hormone disorder, an approved indication, recovery after surgery, body composition, or general longevity? Each needs different evidence.
Direct receptor signaling vs upstream hormone stimulation
CJC-1295 and ipamorelin are upstream signals that stimulate GH release. IGF-1 LR3 is discussed as more downstream and more direct. Direct does not mean safer, and it does not mean more proven. Reviews of GH–IGF-1 performance-enhancing peptides highlight endocrine and metabolic concerns, including dysglycemia, fluid retention, joint or muscle symptoms, and injection-site reactions 8.
Why bodybuilding stack claims exceed the available human evidence
Online stack claims often combine CJC-1295, ipamorelin, and IGF-1 LR3 with dose schedules, cycles, or before-and-after promises. That is not the same as clinical evidence. Current peer-reviewed reviews urge clinicians to separate regulated data from online self-administration protocols and product claims 8.
What does human research show for CJC-1295?
CJC-1295 has human evidence showing changes in GH and IGF-1, but those are biomarker findings. They do not prove that CJC-1295 improves strength, muscle gain, fat loss, recovery, lifespan, or healthspan in healthy adults.
Findings from healthy adult studies
In a randomized controlled trial in healthy adults, CJC-1295 produced prolonged stimulation of GH and IGF-1 secretion 1. Another clinical study reported that pulsatile GH secretion persisted during continuous stimulation with CJC-1295 4.
What changes in GH and IGF-1 can and cannot prove
These studies help explain mechanism. They do not prove patient-important outcomes. A higher IGF-1 level may show that the pathway moved, but it does not tell us whether a person gained strength, lost fat, recovered faster, or lived longer.
Why biomarker changes are not the same as proven muscle, fat-loss, or longevity outcomes
Longevity science has a high bar: longer healthy life in humans. For CJC-1295, available human studies are not the same as a long-term healthspan trial. A phase 2 study of CJC-1295 in HIV patients with visceral obesity was registered, but ClinicalTrials.gov lists it as terminated, so it should not be used as proof of benefit 5.
What does human research show for ipamorelin?
Ipamorelin has human pharmacology data and has been tested in a postoperative ileus setting, but this does not establish anti-aging or bodybuilding benefits. Its evidence is stronger for describing GH response than for proving visible body changes.
Human volunteer pharmacology data
A human volunteer study modeled ipamorelin pharmacokinetics and pharmacodynamics, including GH response 2. This helps researchers understand exposure and hormone response, but it is not a trial showing improved performance or body composition.
Postoperative ileus research
Ipamorelin was also studied in a prospective randomized proof-of-concept trial for postoperative ileus after bowel resection 3. That is a very different clinical question from muscle growth, fat loss, recovery from training, or longevity.
Why these studies do not establish benefits for bodybuilding or anti-aging
A peptide can have a plausible mechanism and still lack proof for a popular use. Reviews of injectable peptide therapy in sports and orthopedics note that evidence varies widely and many uses remain limited or investigational 9.
What evidence exists for IGF-1 LR3?
IGF-1 LR3 has limited direct human outcome evidence for common claims like strength, hypertrophy, recovery, fat loss, or longevity. Most patient-facing claims rely on biology, animal or cell reasoning, or online use patterns rather than controlled human outcomes.
How IGF-1 LR3 is described biologically
IGF-1 LR3 is described as a modified insulin-like growth factor analog. Normal IGF-1 signaling is controlled by binding proteins and feedback loops, so changing that system can have effects beyond muscle tissue 7.
Why direct human outcome evidence is limited
For IGF-1 LR3, the main gap is not that the pathway is irrelevant. The gap is that direct human trials for common performance and longevity claims are limited. A 2026 review of GH–IGF-1 performance-enhancing peptides listed IGF-1 LR3 among agents found in unregulated or online settings and emphasized uncertainty around performance and recomposition claims 8.
What can be inferred from IGF-1 biology—and what cannot
IGF-1 biology is relevant to growth, tissue signaling, metabolism, and muscle repair. But relevance is not proof. You cannot infer a reliable strength gain, recovery timeline, or longevity effect from pathway diagrams alone.
What are the risks of IGF-1 LR3, CJC-1295, and ipamorelin?
The main risks include glucose changes, fluid retention, joint or muscle symptoms, injection-site reactions, endocrine changes, and unknown long-term effects. The risks are harder to judge when peptides come from unlicensed “research chemical” supply chains.
Blood sugar and dysglycemia concerns
GH and IGF-1 signaling interact with glucose metabolism. Reviews of performance-enhancing GH–IGF-1 peptides list dysglycemia among the clinical concerns seen with these compounds and related online protocols 8. People with diabetes, prediabetes, a history of hypoglycemia, or medications that affect glucose need clinician oversight.
Fluid retention, joint pain, and soft-tissue symptoms
Fluid retention, myalgia, and arthralgia are also described concerns in reviews of these peptide categories 8. These symptoms can overlap with training injuries, thyroid issues, medication effects, or inflammatory problems, so self-diagnosis can be misleading.
Possible endocrine effects
Changing the GH–IGF-1 axis can affect more than one lab value. Reviews describe possible endocrine and metabolic disturbances, including changes involving appetite, cortisol, prolactin, and glucose regulation 8.
Mitogenic concerns and why long-term uncertainty matters
IGF-1 is a growth signal. That does not mean every exposure causes harm, but it does mean long-term safety questions matter, especially for people with a cancer history, unexplained symptoms, abnormal labs, or higher baseline risk. Long-term human outcome data for many investigational peptide uses remain limited 8.
Risks from unregulated or research-use supply chains
A major safety issue is not only the molecule; it is the supply chain. No-prescription “research use” vendors may have uncertain identity, potency, sterility, and storage. In contrast, a licensed clinical path uses a medical evaluation, documented prescribing when appropriate, and dispensing through regulated pharmacy channels.
How long does it take to see results from CJC-1295 and ipamorelin?
Hormone changes can happen before visible changes, but visible timelines are not well proven for CJC-1295 and ipamorelin. Online reports are not the same as controlled evidence.
What hormone changes may occur before visible body changes
CJC-1295 studies show GH and IGF-1 biomarker changes in healthy adults 1. Ipamorelin volunteer research modeled GH response 2. These hormone responses can occur without proving a visible change in muscle, fat, skin, or recovery.
Why patient-reported timelines are not the same as clinical proof
Photos, scale changes, and gym logs are affected by training, sleep, calories, hydration, creatine, injury, and other medications. Without a controlled trial, it is hard to know what caused the change.
What clinicians may monitor instead of relying on photos or scale weight
A clinician may focus on symptoms, side effects, medication interactions, glucose risk, relevant labs, and whether the goal has an approved or better-studied path. Monitoring should fit the patient’s medical history, not an online protocol.
3-min quiz
Have questions about peptide options?
Chia does not list CJC-1295, ipamorelin, or IGF-1 LR3 as current treatments. We do offer sermorelin after an online health questionnaire and licensed-provider review, when clinically appropriate. A prescription is never guaranteed. Chia medications are compounded by US state-licensed 503A pharmacies and shipped to your door; compounded drugs are not FDA-approved.
Can IGF-1 LR3 make you stronger?
IGF-1 LR3 is not proven to make healthy adults stronger in controlled human trials. The GH–IGF-1 pathway is relevant to muscle biology, but strength is a whole-body outcome affected by training, nerves, recovery, nutrition, sleep, and injury history.
Why GH–IGF-1 biology is relevant to muscle
IGF-1 signaling is involved in growth and tissue biology, and the GH–IGF-1 axis is one reason these peptides attract interest. But mechanism alone cannot tell us the size, safety, or reliability of a performance effect.
Why stronger does not automatically follow from higher IGF-1 signaling
Strength depends on muscle size, tendon health, motor learning, training plan, and nervous-system adaptation. A higher signaling marker does not automatically mean more force production.
What human performance data are missing
What is missing is the kind of trial that measures strength, lean mass, safety labs, adverse events, and durability over time in the target population. Without that, claims about IGF-1 LR3 and strength remain investigational 8.
How does this compare with sermorelin at Chia?
Sermorelin is a GHRH analog, so it is more similar in concept to upstream GH stimulation than to direct IGF-1 LR3 signaling. At Chia, CJC-1295, ipamorelin, and IGF-1 LR3 are not listed as current treatments; sermorelin is listed in our current catalog.
Chia does not list CJC-1295, ipamorelin, or IGF-1 LR3 as current treatments
We do not present CJC-1295, ipamorelin, or IGF-1 LR3 as medications you can obtain through Chia. If you are researching those peptides online, we encourage you to focus on licensed medical review and evidence quality rather than unverified stack protocols.
Chia offers sermorelin as tablets, nasal spray, and injection through clinician review
Chia offers sermorelin in injection, nasal spray, and tablet forms. Plans for sermorelin injections currently start at $179/month; see the sermorelin product page for current details. Dosing is provider-guided and adjusted over time when treatment is prescribed.
| Chia sermorelin form | How it may fit a patient’s routine | Catalog note |
|---|---|---|
| Injection | May fit patients comfortable with injectable peptide treatment and provider-guided follow-up | Plans currently start at $179/month |
| Nasal spray | May fit patients who prefer a non-injection route when clinically appropriate | Listed in Chia’s current catalog |
| Tablets | May fit patients who prefer an oral option when clinically appropriate | Listed in Chia’s current catalog |
How online evaluation, provider-guided dosing, and 503A compounding work at Chia
Chia care is 100% online. You complete a short health questionnaire, then a licensed US provider reviews your history, goals, medications, and safety factors. If prescribed, medication is compounded in the US by a state-licensed 503A compounding pharmacy and shipped to your door.
When to use the eligibility quiz or ask a licensed clinician about peptide options
If your goal is energy, recovery, body composition, or healthy aging, the first step is not choosing a peptide stack. It is defining the medical question. Our online eligibility quiz helps start that review, and our care team can discuss whether a Chia-listed option is appropriate.
For deeper reading, see our guides on CJC-1295 and ipamorelin vs sermorelin, CJC-1295 and ipamorelin dosage evidence, and whether you can get CJC-1295 and ipamorelin online. You can also read our overview of the sermorelin peptide.
What should you ask a clinician before considering GH–IGF-1 peptides?
The safest question is not “which stack?” It is “what problem are we treating, and what evidence supports this option for me?” A licensed clinician can help separate symptoms, goals, approved options, and monitoring needs.
- 1What specific problem are we trying to address: a diagnosed condition, a symptom pattern, recovery, body composition, or general longevity?
- 2Are there approved options for my condition, and how do their evidence and risks compare?
- 3What medical history matters for me, such as cancer history, diabetes, sleep apnea, edema, joint disease, or endocrine disorders?
- 4Which medications or supplements could interact with glucose, fluid balance, or hormone signaling?
- 5What labs or follow-up would be used to monitor safety?
- 6What side effects should make me stop and contact a clinician?
- 7Is the product coming from a licensed pharmacy, or from an unregulated research-use vendor?
3-min quiz
Start with a clinician-reviewed path
If you want to discuss peptide goals with Chia, you can start with our online eligibility quiz. Chia offers sermorelin in injection, nasal spray, and tablet forms when a licensed provider determines it is clinically appropriate. A prescription requires a medical evaluation and is not guaranteed.
FAQ
Main concerns include blood sugar changes, possible hypoglycemia or dysglycemia, fluid retention, joint or muscle symptoms, endocrine effects, injection reactions, and unknown long-term growth-signal risk. The risk is higher when products come from unregulated research-use vendors instead of licensed medical care.
Hormone changes may occur before visible body changes, but visible timelines for muscle, fat loss, recovery, or anti-aging are not well proven in controlled human trials. Photos and gym changes can be affected by training, sleep, diet, hydration, and other medications.
IGF-1 biology is relevant to muscle, but IGF-1 LR3 is not proven to make healthy adults stronger in controlled human outcome trials. Strength depends on training, nervous-system adaptation, tendon health, nutrition, recovery, and many other factors.
There is no strong human evidence showing that IGF-1 LR3 is better than CJC-1295 for strength, muscle gain, fat loss, recovery, or longevity. IGF-1 LR3 acts closer to IGF-1 signaling, while CJC-1295 stimulates growth hormone upstream; different mechanisms do not prove better outcomes.
No. Both are related to GHRH-type signaling, but they are different peptides. CJC-1295 is often discussed as a longer-acting GHRH analog, while sermorelin is a GHRH analog that Chia lists as a current treatment in injection, nasal spray, and tablet forms.
No. Chia does not list CJC-1295, ipamorelin, or IGF-1 LR3 as current treatments. Chia does offer sermorelin after an online questionnaire and licensed-provider review, when clinically appropriate. A prescription is never guaranteed.
Compounded medications are not FDA-approved. At Chia, listed treatments are prescribed only after a licensed provider reviews medical history, goals, contraindications, medications, and monitoring needs, and prescriptions are filled by state-licensed US 503A compounding pharmacies.
References
- 1.Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism. 2006.
- 2.Gobburu JV, Agersø H, Jusko WJ, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999.
- 3.Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014.
- 4.Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism. 2006.
- 5.ClinicalTrials.gov. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity, NCT00267527. ClinicalTrials.gov. 2026.
- 6.Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews. 2026.
- 7.Yakar S, Werner H, Rosen CJ. Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Care. International Journal of Molecular Sciences. 2021.
- 8.Frontiers in Endocrinology. The emerging landscape of performance-enhancing drugs marketed as research compounds targeting the growth hormone–insulin-like growth factor-1 axis. Frontiers in Endocrinology. 2026.
- 9.Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if sermorelin is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
